Verastem Oncology News and Activities

Verastem Oncology is a company listed under the stock ticker VSTM (US).

View the org chart displaying its 34 main executives

Most searched biographies at Verastem Oncology

• Dan Paterson, President and Chief Executive Officer
• Paul Bunn, Director
• Michelle Robertson, Director

Popular executive movements at Verastem Oncology

• Daniel Lyons has joined the company as Chief Commercial Officer  (posted on May 26 2026).
• Matthew Ros, who is Chief Operating Officer will soon leave the company  (posted on December 16 2025).
• John Johnson, who was Director, is promoted to Chairman of the Board  (posted on December 16 2025).

Create your alert
to follow the executive moves at Verastem Oncology.

Verastem Oncology has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Verastem Oncology

• Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer | Verastem, Inc.
• Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference | Verastem, Inc.
• Press Releases | Verastem, Inc.
• Press Releases | Verastem, Inc.
• Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates | Verastem, Inc.
• Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer | Verastem, Inc.
• Press Releases | Verastem, Inc.
• Verastem Oncology to Participate in Upcoming Investor Conferences | Verastem, Inc.
• Press Releases | Verastem, Inc.
• Press Releases | Verastem, Inc.
• View more press releases Close

Social media about Verastem Oncology

• Verastem Oncology on Wikipedia, Google News & Yahoo Finance
• Verastem Oncology on LinkedIn, X (Twitter) & YouTube